Remiges Ventures

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

KisoJi Biotechnology is an early-stage biotechnology company focused on the development of innovative antibodies for cancer treatment and other therapeutic indications. The company employs a unique approach that allows for the comprehensive identification and visualization of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's antibody platform features multi-species single-domain antibody transgenic mice and utilizes AI-driven antibody fingerprinting to match specific epitopes on various targets. This technology enables the creation of robust, easily manufacturable multi-specific antibodies, aimed at significantly improving treatment outcomes for cancer patients. Through its advanced methodologies, KisoJi is positioned to enhance the efficacy of cancer therapies and contribute to the broader field of oncology.

Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

Cyrano Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for individuals suffering from taste and smell disorders. Founded in 2014 and based in Washington, D.C., the company is working on an intranasal product, CYR-001, which repurposes an existing approved molecule, Theophylline, to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, CYR-001 demonstrated promising results, with eight out of ten participants showing significant improvements within two weeks and no reported side effects. The company's approach includes a diagnostic kit designed to assess and quantify the severity of sensory loss, thereby aiding caregivers in enhancing the quality of life for affected patients, including those undergoing chemotherapy who often experience changes in their sensory perception.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

KUPANDO is an innovative biopharmaceutical company focused on developing TLR 4/7 agonists to enhance innate immunity. The company aims to deliver safe and affordable immunotherapy options for cancer patients, while also creating immunostimulatory drugs designed to prevent infectious diseases. KUPANDO's research targets toll-like receptors that play a crucial role in identifying cancer and infection markers, which subsequently activate the innate immune system. By concentrating on these mechanisms, KUPANDO seeks to provide effective treatment solutions for both cancer and infectious diseases, making significant strides in the field of immunotherapy.

Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Viage Therapeutics is a neuroscience company established in 2018, focusing on the development of innovative neurotherapeutics. The company is dedicated to discovering and creating a new class of drugs aimed at treating psychiatric and inflammatory diseases, including conditions such as depression, anxiety, and gastrointestinal disorders. Through its groundbreaking research, Viage Therapeutics seeks to address significant unmet medical needs, providing healthcare professionals with access to novel therapeutic options that could improve patient outcomes.

Capacity Bio is a therapeutics company dedicated to the field of mitophagy, which involves the process of removing damaged mitochondria to maintain cellular health. The company is focused on developing a comprehensive and advanced platform for mitophagy therapeutics aimed at restoring mitochondrial quality control in various diseases. By targeting fundamental biological processes, Capacity Bio seeks to deliver radical therapeutic benefits that can enhance healthcare outcomes. The company's innovative approach positions it at the forefront of mitochondrial research and therapeutic development.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Cyrano Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for individuals suffering from taste and smell disorders. Founded in 2014 and based in Washington, D.C., the company is working on an intranasal product, CYR-001, which repurposes an existing approved molecule, Theophylline, to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, CYR-001 demonstrated promising results, with eight out of ten participants showing significant improvements within two weeks and no reported side effects. The company's approach includes a diagnostic kit designed to assess and quantify the severity of sensory loss, thereby aiding caregivers in enhancing the quality of life for affected patients, including those undergoing chemotherapy who often experience changes in their sensory perception.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Tranquis Therapeutics, Inc. is a biotechnology company based in San Mateo, California, focused on developing innovative immuno-therapeutics for neurodegenerative and aging-related diseases. Founded in 2016, the company emerged from pioneering neuro-immunology research and is dedicated to addressing the dysfunction of myeloid immune cells that plays a significant role in various nervous system disorders. Tranquis’ lead therapeutic candidate, TQS-168, is designed to treat conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, and age-related cognitive impairment. The company's approach involves small molecules capable of crossing the blood-brain barrier, and it aims to initiate clinical development in orphan diseases like ALS and FTD before expanding to more common disorders, including Parkinson's and Alzheimer's disease. Tranquis Therapeutics strives to reduce the burden of these illnesses on patients, families, and society at large through its novel therapies.

OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

ENB Therapeutics, Inc. is a biopharmaceutical company based in New York, New York, that specializes in developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015, the company focuses on overcoming drug resistance, a significant issue affecting over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class selective endothelin B receptor (ETBR) inhibitor that has demonstrated the ability to significantly reduce tumor growth and enhance survival in preclinical studies. ENB-001 works by restoring T-cell infiltration into tumors, inhibiting metastasis, and improving the efficacy of immunotherapy. The product has received Orphan Drug Designation from the FDA, granting it market exclusivity and a robust intellectual property position. ENB Therapeutics is also developing a companion diagnostic to identify patients who could benefit from ENB-001, thus broadening its potential applications within the multi-billion-dollar immunotherapy market. The company's innovative approach aims to set a new standard of care by combining its therapies with existing immuno-oncology treatments to combat drug resistance and stimulate immune responses against cancer.

KisoJi Biotechnology is an early-stage biotechnology company focused on the development of innovative antibodies for cancer treatment and other therapeutic indications. The company employs a unique approach that allows for the comprehensive identification and visualization of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's antibody platform features multi-species single-domain antibody transgenic mice and utilizes AI-driven antibody fingerprinting to match specific epitopes on various targets. This technology enables the creation of robust, easily manufacturable multi-specific antibodies, aimed at significantly improving treatment outcomes for cancer patients. Through its advanced methodologies, KisoJi is positioned to enhance the efficacy of cancer therapies and contribute to the broader field of oncology.

OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

Mitoconix Bio Ltd is a biotechnology company established in 2016 and headquartered in Jerusalem, Israel, focused on developing innovative therapies aimed at enhancing mitochondrial health to treat neurodegenerative diseases. The company employs a disease-modifying approach that targets the functions of mitochondria, which are essential for generating ATP, regulating calcium, and maintaining cellular balance. Mitochondria play a crucial role in neuron function, undergoing constant changes in structure through processes known as fission and fusion. Disruptions in these processes can lead to reduced energy production and increased oxidative stress, contributing to cellular dysfunction and death. Mitoconix's lead drug is a first-in-class inhibitor designed to counteract pathological mitochondrial fragmentation and has shown promising efficacy in preclinical models of Huntington's disease and Parkinson's disease, as well as beneficial effects in patient-derived cells associated with these conditions and Alzheimer's disease.